GT200600442A - Inhibidores de pde y combinaciones de los mismos para el tratamiento de trastornos urologicos - Google Patents
Inhibidores de pde y combinaciones de los mismos para el tratamiento de trastornos urologicosInfo
- Publication number
- GT200600442A GT200600442A GT200600442A GT200600442A GT200600442A GT 200600442 A GT200600442 A GT 200600442A GT 200600442 A GT200600442 A GT 200600442A GT 200600442 A GT200600442 A GT 200600442A GT 200600442 A GT200600442 A GT 200600442A
- Authority
- GT
- Guatemala
- Prior art keywords
- treatment
- combinations
- same
- urological disorders
- pde inhibitors
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/34—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase
- C12Q1/44—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase involving esterase
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2500/00—Screening for compounds of potential therapeutic value
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Urology & Nephrology (AREA)
- Biophysics (AREA)
- Biotechnology (AREA)
- Diabetes (AREA)
- Microbiology (AREA)
- Molecular Biology (AREA)
- Endocrinology (AREA)
- Analytical Chemistry (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Physics & Mathematics (AREA)
- Pain & Pain Management (AREA)
- Reproductive Health (AREA)
- Transplantation (AREA)
- Gynecology & Obstetrics (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Rheumatology (AREA)
- Epidemiology (AREA)
Abstract
LA PRESENTE INVENCION PROPORCIONA COMPOSICIONES FARMACOLOGICAS QUE COMPRENDEN INHIBIDORES DE PDE-5 Y PDE-4, SOLOS O EN COMBINACION, PARA EL TRATAMIENTO DE TRASTORNOS UROLOGICOS QUE COMPRENDEN HIPERPLASIA PROSTATICA BENIGNA, SINTOMAS DEL TRACTO URINARIO INFERIOR Y EN PARTICULAR SINTOMAS IRRITATIVOS PROVOCADOS POR OBSTRUCCION DE LA SALIDA DE LA VEJIGA. T2006
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP05021261 | 2005-09-29 | ||
EP06007776 | 2006-04-13 |
Publications (1)
Publication Number | Publication Date |
---|---|
GT200600442A true GT200600442A (es) | 2007-05-15 |
Family
ID=37831473
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
GT200600442A GT200600442A (es) | 2005-09-29 | 2006-09-29 | Inhibidores de pde y combinaciones de los mismos para el tratamiento de trastornos urologicos |
Country Status (23)
Country | Link |
---|---|
US (1) | US20090186896A1 (es) |
EP (1) | EP1931797A2 (es) |
JP (1) | JP2009509984A (es) |
KR (1) | KR20080056250A (es) |
AR (1) | AR057867A1 (es) |
AU (1) | AU2006299232A1 (es) |
BR (1) | BRPI0616633A2 (es) |
CA (1) | CA2623657A1 (es) |
CR (1) | CR9840A (es) |
DO (1) | DOP2006000207A (es) |
EC (1) | ECSP088311A (es) |
GT (1) | GT200600442A (es) |
IL (1) | IL190201A0 (es) |
MA (1) | MA29880B1 (es) |
NO (1) | NO20081973L (es) |
PE (1) | PE20070587A1 (es) |
RU (1) | RU2435588C2 (es) |
SG (1) | SG166106A1 (es) |
SV (1) | SV2009002851A (es) |
TN (1) | TNSN08147A1 (es) |
TW (1) | TW200804603A (es) |
UY (1) | UY29816A1 (es) |
WO (1) | WO2007039075A2 (es) |
Families Citing this family (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2007113243A2 (en) * | 2006-03-31 | 2007-10-11 | Investigación Y Clínica Andrológicas S.L. | Use of pde 5 inhibitors for the treatment of overactive bladder |
RU2009145935A (ru) * | 2007-05-12 | 2011-06-20 | Байер Шеринг Фарма Акциенгезельшафт (DE) | Стимуляторы ргц, активаторы ргц и комбинации для лечения урологических нарушений |
WO2008157205A2 (en) * | 2007-06-15 | 2008-12-24 | Duke University | Methods and compositions for treating urinary tract infections using agents that mimic or elevate cyclic amp |
JP2010540621A (ja) * | 2007-10-02 | 2010-12-24 | ドン ア ファーマシューティカル カンパニー リミテッド | 良性前立腺肥大症および下部尿路症状の治療または予防用組成物、およびその治療または予防方法 |
EP2222639A1 (en) * | 2007-11-21 | 2010-09-01 | Decode Genetics EHF | Biaryl pde4 inhibitors for treating pulmonary and cardiovascular disorders |
EP2156847A1 (en) * | 2008-08-19 | 2010-02-24 | Sanofi-Aventis | New combination of active ingredients containing an alpha1-antagonist and a PDE 4 inhibitor. |
EP2266567A1 (en) | 2009-05-26 | 2010-12-29 | Æterna Zentaris GmbH | Use of cetrorelix in combination with PDE V inhibitors for the treatment of sex hormone dependent disorders |
EP2266568A1 (en) | 2009-05-26 | 2010-12-29 | Æterna Zentaris GmbH | Use of LHRH antagonists in combination with PDE V inhibitors for the treatment of sex hormone dependent disorders |
JP2011184433A (ja) * | 2010-02-09 | 2011-09-22 | Daiichi Sankyo Healthcare Co Ltd | バルデナフィル含有内服液剤組成物 |
JO3264B1 (ar) | 2013-03-13 | 2018-09-16 | Lilly Co Eli | مركبات ازيتيدينيل أوكسي فينيل بيروليدين |
KR102239291B1 (ko) * | 2013-06-28 | 2021-04-14 | 한미약품 주식회사 | 타다라필 또는 이의 약학적으로 허용가능한 염을 포함하는 저작정 제제 |
EP3082428A4 (en) | 2013-12-09 | 2017-08-02 | Respira Therapeutics, Inc. | Pde5 inhibitor powder formulations and methods relating thereto |
EP3092231B1 (en) * | 2013-12-11 | 2018-06-27 | Ironwood Pharmaceuticals, Inc. | Sgc stimulators |
TN2017000029A1 (en) | 2014-08-12 | 2018-07-04 | Mezzion Pharma Co Ltd | Methods of improving myocardial performance in fontan patients using udenafil compositions |
WO2016033776A1 (en) | 2014-09-04 | 2016-03-10 | Eli Lilly And Company | Crystalline (2s) -3- [ (3s, 4s) -3- [ (1r) -1-hydroxyethyl] -4- (4-methoxy-3- { [1- (5-methylpyridin-2-yl) azetidin-3-yl] oxy} phenyl) -3-methylpyrrolidin-1-yl] -3-oxopropane-1, 2-diol |
TW201625591A (zh) | 2014-09-12 | 2016-07-16 | 美國禮來大藥廠 | 吖丁啶基氧苯基吡咯啶化合物 |
PT3562485T (pt) | 2018-03-23 | 2020-08-27 | Laboratoires Major | Composições e métodos não hormonais para contraceção masculina compreendendo (r)-silodosina |
JP2022518292A (ja) * | 2019-01-23 | 2022-03-14 | パス セラピューティクス,インク. | ホスホジエステラーゼ4(pde4)阻害によるてんかんの治療方法 |
Family Cites Families (65)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US2705715A (en) * | 1952-10-29 | 1955-04-05 | American Cyanamid Co | Purine compounds and methods of preparing the same |
CH367510A (de) * | 1957-11-27 | 1963-02-28 | Ciba Geigy | Verfahren zur Herstellung neuer Sulfonamide |
GB1051734A (es) * | 1963-01-16 | |||
GB1042471A (en) * | 1963-01-16 | 1966-09-14 | Ilford Ltd | Penta-azaindenes, their production and use in photographic emulsions |
US3169129A (en) * | 1963-05-10 | 1965-02-09 | American Cyanamid Co | 2-ortho-hydroxy-phenyl-4-(3h)-quinazolinones |
USRE26565E (en) * | 1966-03-02 | 1969-04-29 | Table iii | |
GB1493685A (en) * | 1970-12-15 | 1977-11-30 | May & Baker Ltd | 8-azapurinones |
BE791025A (fr) * | 1971-11-19 | 1973-05-07 | Allen & Hanburys Ltd | Composes heterocycliques |
GB1457873A (en) * | 1973-01-04 | 1976-12-08 | Allen & Hanburys Ltd | Imidazotriazines |
US4052390A (en) * | 1973-06-12 | 1977-10-04 | May & Baker Limited | Azapurinones |
US4060615A (en) * | 1976-02-18 | 1977-11-29 | Mead Johnson & Company | 2-Piperazinyl-6,7-dimethoxyquinazolines |
GB1561345A (en) * | 1976-10-22 | 1980-02-20 | May & Baker Ltd | 8 - azapuring - 6 - ones |
US4159330A (en) * | 1976-11-02 | 1979-06-26 | Carlo Erba S.P.A. | 2-Disubstituted phenyl-3,4-dihydro-4-oxo-quinazoline derivatives and process for their preparation |
DK109578A (da) * | 1977-03-25 | 1978-09-26 | Allen & Hanburys Ltd | Fremgangsmaade til fremstilling af heterocycliske forbindelser |
DE3166627D1 (en) * | 1980-12-12 | 1984-11-15 | Thomae Gmbh Dr K | Pyrimidones, their preparation and medicines containing them |
US4431440A (en) * | 1981-02-20 | 1984-02-14 | American Cyanamid Company | Method to alter or control the development and/or the life cycle of various plant species |
US4666908A (en) * | 1985-04-05 | 1987-05-19 | Warner-Lambert Company | 5-Substituted pyrazolo[4,3-d]pyrimidine-7-ones and methods of use |
CA1303037C (en) * | 1987-02-02 | 1992-06-09 | Smith Kline & French Laboratories Limited | Purinone derivatives as bronchodilators vasodilators and anti-allergic agents |
US5254571A (en) * | 1988-04-21 | 1993-10-19 | Smith Kline & French Laboratories Ltd. | Chemical compounds |
EP0347146B1 (en) * | 1988-06-16 | 1993-09-01 | Smith Kline & French Laboratories Limited | Fused pyrimidine derivatives, process and intermediates for their preparation and pharmaceutical compositions containing them |
US5075310A (en) * | 1988-07-01 | 1991-12-24 | Smith Kline & French Laboratories, Ltd. | Pyrimidone derivatives as bronchodilators |
US4923874A (en) * | 1988-07-21 | 1990-05-08 | G. D. Searle & Co. | Use of 8-azapurin-6-one derivatives for control of hypertension |
GB8817651D0 (en) * | 1988-07-25 | 1988-09-01 | Smith Kline French Lab | Chemical compounds |
GB8827988D0 (en) * | 1988-11-30 | 1989-01-05 | Smith Kline French Lab | Chemical compounds |
US5574020A (en) * | 1989-09-28 | 1996-11-12 | Eli Lilly And Company | Tilmicosin formulation |
HUT64220A (en) * | 1990-04-11 | 1993-12-28 | Upjohn Co | Process for producing chewable tablet containing ibuprophene with taste inhibitor |
US5250534A (en) * | 1990-06-20 | 1993-10-05 | Pfizer Inc. | Pyrazolopyrimidinone antianginal agents |
GB9114760D0 (en) * | 1991-07-09 | 1991-08-28 | Pfizer Ltd | Therapeutic agents |
US5316906A (en) * | 1991-08-23 | 1994-05-31 | Molecular Probes, Inc. | Enzymatic analysis using substrates that yield fluorescent precipitates |
GB9126260D0 (en) * | 1991-12-11 | 1992-02-12 | Pfizer Ltd | Therapeutic agents |
US5294612A (en) * | 1992-03-30 | 1994-03-15 | Sterling Winthrop Inc. | 6-heterocyclyl pyrazolo [3,4-d]pyrimidin-4-ones and compositions and method of use thereof |
US5734053A (en) * | 1992-06-26 | 1998-03-31 | Pfizer Inc | Purinone antianginal agents |
GB9218322D0 (en) * | 1992-08-28 | 1992-10-14 | Pfizer Ltd | Therapeutic agents |
US6143746A (en) * | 1994-01-21 | 2000-11-07 | Icos Corporation | Tetracyclic cyclic GMP-specific phosphodiesterase inhibitors, process of preparation and use |
US5556847A (en) * | 1994-10-27 | 1996-09-17 | Duquesne University Of The Holy Ghost | Methods of effecting memory enhancement mediated by steroid sulfatase inhibitors |
GB9423911D0 (en) * | 1994-11-26 | 1995-01-11 | Pfizer Ltd | Therapeutic agents |
DE19540642A1 (de) * | 1995-11-01 | 1997-05-07 | Stief Christian Georg Priv Doz | Verwendung von Inhibitoren der Phosphodiesterase bei der Behandlung von Prostataerkrankungen |
US6548490B1 (en) * | 1997-10-28 | 2003-04-15 | Vivus, Inc. | Transmucosal administration of phosphodiesterase inhibitors for the treatment of erectile dysfunction |
ATE213246T1 (de) * | 1997-11-12 | 2002-02-15 | 2-phenyl-substituierte imidazotriazinone als phosphodiesterase inhibitoren | |
US6221402B1 (en) * | 1997-11-20 | 2001-04-24 | Pfizer Inc. | Rapidly releasing and taste-masking pharmaceutical dosage form |
GT199900061A (es) * | 1998-05-15 | 2000-10-14 | Pfizer | Formulaciones farmaceuticas. |
DE19827640A1 (de) * | 1998-06-20 | 1999-12-23 | Bayer Ag | 7-Alkyl- und Cycloalkyl-substituierte Imidazotriazinone |
IL132406A0 (en) * | 1998-10-21 | 2001-03-19 | Pfizer Prod Inc | Treatment of bph with cgmp elevators |
UA67802C2 (uk) * | 1998-10-23 | 2004-07-15 | Пфайзер Рісьоч Енд Дівелепмент Компані, Н.В./С.А. | Фармацевтична композиція з контрольованим вивільненням інгібітора цгмф фде-5 (варіанти), спосіб її одержання та спосіб лікування еректильної дисфункції |
WO2001017480A2 (en) * | 1999-09-09 | 2001-03-15 | Androsolutions, Inc. | Methods and compositions for preventing and treating urinary tract disorders |
US6075028A (en) * | 1999-09-23 | 2000-06-13 | Graham; Richard | Method of treating Tourette's syndrome and related CNS disorders |
US6503908B1 (en) * | 1999-10-11 | 2003-01-07 | Pfizer Inc | Pharmaceutically active compounds |
IL150022A0 (en) * | 1999-12-24 | 2002-12-01 | Bayer Ag | Imidazo [1,3,5] triazinones and the use thereof |
US6774128B2 (en) * | 2000-04-19 | 2004-08-10 | Johns Hopkins University | Methods for prevention and treatment of gastrointestinal disorders |
AU2001278673A1 (en) * | 2000-10-30 | 2002-05-15 | Lupin Limited | Rapidly disintegrating sustained release cefuroxime axetil composition |
UA80393C2 (uk) * | 2000-12-07 | 2007-09-25 | Алтана Фарма Аг | Фармацевтична композиція, яка містить інгібітор фде 4, диспергований в матриці |
ATE472319T1 (de) * | 2001-02-15 | 2010-07-15 | Mitsubishi Tanabe Pharma Corp | Tabletten, die in der mundhöhle schnell zerfallen |
DE10118306A1 (de) * | 2001-04-12 | 2002-10-17 | Bayer Ag | Imidazotriazinonhaltige Zusammensetzungen zur nasalen Applikation |
DK1392314T3 (da) * | 2001-05-09 | 2007-03-12 | Bayer Healthcare Ag | Hidtil ukendt anvendelse af 2-[2-ethoxy-5-(4-methyl-piperazin-1-sulfonyl)-phenyl]-5-methyl-7-propyl-3H-imidazo[5,1-f][1,2,4]-triazin-4-on |
GB0129274D0 (en) * | 2001-12-06 | 2002-01-23 | Pfizer Ltd | Novel kit |
US7118765B2 (en) * | 2001-12-17 | 2006-10-10 | Spi Pharma, Inc. | Co-processed carbohydrate system as a quick-dissolve matrix for solid dosage forms |
US7939102B2 (en) * | 2002-06-07 | 2011-05-10 | Torrent Pharmaceuticals Ltd. | Controlled release formulation of lamotrigine |
DE10232113A1 (de) * | 2002-07-16 | 2004-01-29 | Bayer Ag | Vardenafil Hydrochlorid Trihydrat enthaltende Arzneimittel |
DE10325813B4 (de) * | 2003-06-06 | 2007-12-20 | Universitätsklinikum Freiburg | Prophylaxe und/oder Therapie bei der portalen Hypertonie |
ES2378374T3 (es) * | 2003-11-20 | 2012-04-11 | Astellas Pharma Inc. | Inhibidores de la PDE 4 para el tratamiento de la cistitis intersticial |
WO2005105073A1 (en) * | 2004-04-27 | 2005-11-10 | Medicinova, Inc. | Phenoxyalkycarboxylic acid derivatives in the treatment of inflammatory diseases |
DE102004023069A1 (de) * | 2004-05-11 | 2005-12-08 | Bayer Healthcare Ag | Neue Darreichungsformen des PDE 5-Inhibitors Vardenafil |
US20070004745A1 (en) * | 2005-03-25 | 2007-01-04 | Schering-Plough Corporation | Methods of treating benign prostatic hyperplasia or lower urinary tract symptoms by using PDE 5 inhibitors |
US20070031349A1 (en) * | 2005-06-23 | 2007-02-08 | David Monteith | Rapidly absorbing oral formulations of PDE 5 inhibitors |
RU2009145935A (ru) * | 2007-05-12 | 2011-06-20 | Байер Шеринг Фарма Акциенгезельшафт (DE) | Стимуляторы ргц, активаторы ргц и комбинации для лечения урологических нарушений |
-
2006
- 2006-09-16 BR BRPI0616633-4A patent/BRPI0616633A2/pt not_active Application Discontinuation
- 2006-09-16 SG SG201007122-3A patent/SG166106A1/en unknown
- 2006-09-16 RU RU2008116547/15A patent/RU2435588C2/ru not_active IP Right Cessation
- 2006-09-16 JP JP2008532632A patent/JP2009509984A/ja active Pending
- 2006-09-16 WO PCT/EP2006/009040 patent/WO2007039075A2/en active Application Filing
- 2006-09-16 KR KR1020087010192A patent/KR20080056250A/ko not_active Application Discontinuation
- 2006-09-16 CA CA002623657A patent/CA2623657A1/en not_active Abandoned
- 2006-09-16 AU AU2006299232A patent/AU2006299232A1/en not_active Abandoned
- 2006-09-16 US US11/992,779 patent/US20090186896A1/en not_active Abandoned
- 2006-09-16 EP EP06777192A patent/EP1931797A2/en not_active Ceased
- 2006-09-27 AR ARP060104226A patent/AR057867A1/es not_active Application Discontinuation
- 2006-09-28 UY UY29816A patent/UY29816A1/es not_active Application Discontinuation
- 2006-09-28 DO DO2006000207A patent/DOP2006000207A/es unknown
- 2006-09-28 TW TW095135881A patent/TW200804603A/zh unknown
- 2006-09-28 PE PE2006001188A patent/PE20070587A1/es not_active Application Discontinuation
- 2006-09-29 GT GT200600442A patent/GT200600442A/es unknown
-
2008
- 2008-03-17 IL IL190201A patent/IL190201A0/en unknown
- 2008-03-26 SV SV2008002851A patent/SV2009002851A/es not_active Application Discontinuation
- 2008-03-26 EC EC2008008311A patent/ECSP088311A/es unknown
- 2008-03-27 CR CR9840A patent/CR9840A/es not_active Application Discontinuation
- 2008-03-28 TN TNP2008000147A patent/TNSN08147A1/en unknown
- 2008-04-23 MA MA30864A patent/MA29880B1/fr unknown
- 2008-04-24 NO NO20081973A patent/NO20081973L/no not_active Application Discontinuation
Also Published As
Publication number | Publication date |
---|---|
TNSN08147A1 (en) | 2009-07-14 |
UY29816A1 (es) | 2007-04-30 |
WO2007039075A3 (en) | 2007-06-21 |
DOP2006000207A (es) | 2007-07-15 |
TW200804603A (en) | 2008-01-16 |
PE20070587A1 (es) | 2007-08-17 |
AU2006299232A1 (en) | 2007-04-12 |
KR20080056250A (ko) | 2008-06-20 |
RU2008116547A (ru) | 2009-11-10 |
JP2009509984A (ja) | 2009-03-12 |
US20090186896A1 (en) | 2009-07-23 |
IL190201A0 (en) | 2008-11-03 |
CR9840A (es) | 2008-10-31 |
BRPI0616633A2 (pt) | 2011-06-28 |
NO20081973L (no) | 2008-06-20 |
CA2623657A1 (en) | 2007-04-12 |
SG166106A1 (en) | 2010-11-29 |
AR057867A1 (es) | 2007-12-26 |
WO2007039075A2 (en) | 2007-04-12 |
ECSP088311A (es) | 2008-06-30 |
RU2435588C2 (ru) | 2011-12-10 |
SV2009002851A (es) | 2009-01-14 |
EP1931797A2 (en) | 2008-06-18 |
MA29880B1 (fr) | 2008-10-03 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
GT200600442A (es) | Inhibidores de pde y combinaciones de los mismos para el tratamiento de trastornos urologicos | |
NO20072558L (no) | Mitotiske kineseinhibitorer og fremgangsmater for anvendelse derav | |
PA8624201A1 (es) | Inhibidores de proteina quinasas con estructura de 3-quinolincarbonitrilo | |
PA8663501A1 (es) | Derivados de indol, benzotiofeno, benzofurano e indeno cicloalquilcondensados | |
CL2007001996A1 (es) | Compuestos derivados de heteroarilos nitrogenados sustituidos con fenilo, inhibidores de la produccion de citoquinas; composicion farmaceutica que los comprende; y sus usos en el tratamiento del cancer, infecciones, enfermedades inflamatorias y autoinmunes. | |
GT200900283A (es) | "terapia de combinación con un compuesto actuando como un inhibidor del receptor adp plaquetario". | |
EA201070127A1 (ru) | Способы лечения легочной гипертензии, родственных заболеваний и нарушений и композиции для их осуществления | |
CR8929A (es) | Polimorfo ii de rapamicina y usos del mismo | |
ECSP067116A (es) | Antagonistas del receptor 2 de citocina quimioatrayente de sales cuaternarias | |
HN2008001464A (es) | Formulaciones para administrcion parenteral de compuestos y sus usos | |
ECSP078013A (es) | Inhibidores heterocíclicos de mek y métodos de uso de ellos | |
DOP2006000054A (es) | Antagonistas del receptor de pgd2 para el tratamiento de enfermedades inflamatorias | |
ECSP11010796A (es) | Compuestos de pirimidina, composiciones y métodos de uso | |
UY29796A1 (es) | Nuevos compuestos para el tratamiento de trastornos neurológicos, psiquiátricos o del dolor | |
CR11582A (es) | Compuestos heterociclicos y sus usos | |
ECSP109878A (es) | Anticuerpos anti-cd79b e inmunoconjugados y métodos de uso de los mismos | |
ATE420883T1 (de) | Pyrrolopyrimidine verwendbar als protein kinase inhibitoren | |
HN2004000319A (es) | "{ 1,8}naftiridin-2-onas y compuestos relacionados para el tratamiento de la esquizofrenia" | |
ECSP109940A (es) | Anticuerpos anti-cd79b e inmunoconjugados humanizados y métodos de uso | |
GT200800198A (es) | Compuestos y composiciones como inhibidores de la actividad del receptor canabinoide del tipo 1. | |
CL2008000089A1 (es) | Compuestos derivados de 2,4-pirimidinona condensada con un heterociclo, inhibidores de pde-4; composicion farmaceutica; combinacion farmaceutica; procedimiento de preparacion de los compuestos, utiles para tratar trastornos inmunes e inflamatorios. | |
UY29414A1 (es) | Derivados de pirimidina para el tratamiento de trastornos hiperproliferativos | |
CL2011000489A1 (es) | Compuestos derivados de pirimido[5,4-d]pirimidina, los cuales actuan como inhibidores de tirosina-quinasas; y composiciones farmaceuticas que los comprenden, utiles en el tratamiento de enfermedades que se caracterizan por una proliferacion celular excesiva o anomala | |
UY30627A1 (es) | Inhibidores de metaloproteasas derivados de heterociclos | |
ECSP045021A (es) | Terapia de combinacion para el tratamiento del cancer |